# Intervention of Engineered Immune Effector T Cells Against Lung Cancer

> **NCT03353428** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Shenzhen Geno-Immune Medical Institute**

## Conditions studied

- Lung Cancer
- NSCLC

## Interventions

- **BIOLOGICAL:** LC-CTLs

## Key facts

- **NCT ID:** NCT03353428
- **Lead sponsor:** Shenzhen Geno-Immune Medical Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-11-15
- **Primary completion:** 2019-01
- **Final completion:** 2020-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** combine with NCT03356808
- **Last updated:** 2018-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03353428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03353428, "Intervention of Engineered Immune Effector T Cells Against Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03353428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*